In this article, we will discuss Ramucirumab (16). So, let’s get started.
Ramucirumab is an antiangiogenic therapy that can increase the risk of gastrointestinal perforation, a potentially fatal event. Four of 570 patients (0.7%) who received Ramucirumab as a single agent in clinical trials experienced gastrointestinal perforation. In Study 2, the incidence of gastrointestinal perforations was also increased in patients that received Ramucirumab plus paclitaxel (1.2%) as compared to patients receiving placebo plus paclitaxel (0.3%). Permanently discontinue Ramucirumab in patients who experience a gastrointestinal perforation.